Dr Reddy's Labs and Alvotech Ink Pact To Commercialize Denosumab Biosimilar

Dr Reddy's Labs SA has forayed into a license and supply contract with Iceland-based biotech player Alvotech for the commercialisation of AVT03, the latter’s  denosumab biosimilar candidate. ATV03 is a biosimilar candidate for Prolia and Xgeva, both of which are used to treat osteoporosis in postmenopausal women and prevent skeletal-related events in adults with advanced cancers.

As part of the agreement, Dr. Reddy's will be in charge of the product's registration and commercialization in the relevant markets, while Alvotech will be in charge of the product development and manufacturing. Dr Reddy's will get elite commercialisation privileges for the US market as a component of the arrangement alongside semi-selective freedoms for Europe and the UK markets, Dr Reddy's added on Tuesday.

As a feature of the licencing pact, Alvotech will receive forthright and improvement and administrative achievement payments of US$38 million notwithstanding certain achievement based business achievement payment of up to US$29 million. The two players said the essential tie-up will unite Dr Reddy's worldwide business presence with Alvotech's demonstrated abilities in creating biosimilars for business sectors universally.

Dr Reddy’s CEO Erez Israeli said the collaboration will make the denosumab biosimilar available to patients in the US, Europe and UK. “This strategic collaboration augments our growing portfolio of biosimilar offerings and progresses our biosimilar journey further into highly regulated markets,” he said.